Drugs / Flutiform
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02063139 | Feb → Jun 2014 | asthma | Mundipharma Research Limited | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00734318 | Sep 2008 → Jun 2009 | asthma | Mundipharma Research Limited | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01099722 Comparator | Apr → Nov 2010 | asthma | Mundipharma Research Limited | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-18 | Mundipharma Research Limited | Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered- dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint mundipharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FlutiForm | “fluticasone propionate / formoterol spray (flutiform®) 200/20 micrograms per day” NCT02063139 ↗ |
| Route | Inhaled | “inhaler 2 puffs bd daily” NCT01099722 ↗ |